Hot Products
0102030405
Benfotiamine: Lipid-Soluble Vitamin B1 from China | High Bioavailability | Trusted Suppliers & Factory
C19H23N4O6PS
As a synthetic derivative of vitamin B1 (thiamine), benfotiamine significantly surpasses ordinary vitamin B1 in bioavailability, targeting and clinical efficacy through structural optimization and pharmacokinetic improvement. The specific advantages are as follows:
1
Structural Innovation: Lipid-Soluble Modification Breaks Through Absorption Limitations
Ordinary vitamin B1 (thiamine) is a water-soluble molecule that relies on intestinal sodium-dependent carriers (ThTr1/2) for active transport. It has a low absorption rate <5% and is easily saturated. High doses are easily excreted. Benfotiamine is converted into a lipid-soluble prodrug by introducing benzoyl and phosphate groups (structural formula C19H23N4O6PS), which can bypass carrier restrictions and directly penetrate intestinal mucosal cells through passive diffusion. The absorption efficiency is increased to more than 80%, and the bioavailability is 3–5× vs ordinary B1 (J Clin Pharmacol, 2008).
2
Pharmacokinetic Advantages: Long-Term Effect and Tissue Targeting
Ordinary B1 has a short half-life in the blood (about 3.5 hours) and is easily cleared quickly by the kidneys. Benfotiamine is hydrolyzed into active thiamine by phosphatase in the body and further converted into thiamine pyrophosphate (TPP). Its lipid solubility makes it easier to accumulate in the phospholipid layer of the cell membrane, prolonging the duration of action half-life >6 hours. At the same time, its ability to penetrate the blood-brain barrier and nerve sheath is 8–10× vs ordinary B1 (Neurochem Res, 2016), and it can effectively act on the central and peripheral nervous systems.
3
Metabolic Regulation: Multi-Target Inhibition of Glucotoxic Damage
In a hyperglycemic environment, ordinary B1 is difficult to effectively inhibit abnormal glucose metabolism pathways due to poor tissue permeability. Benfotiamine shows unique advantages through the following mechanisms:
- 🔬 Blocking AGEs Generation: Inhibiting hexosamine and polyol pathways, reducing the accumulation of advanced glycation end products (AGEs), and alleviating axonal damage in diabetic neuropathy (Diabetes, 2010).
- 🛡️ Anti-Inflammatory & Antioxidant: Downregulating the activity of NF-κB and TXNIP/NLRP3 inflammasomes, reducing inflammatory factors such as IL-6 and TNF-α, while enhancing glutathione reductase activity and alleviating oxidative stress.
- ⚡ Mitochondrial Protection: Restoring the function of pyruvate dehydrogenase complex (PDH), improving the efficiency of tricarboxylic acid cycle, and reducing lactic acid accumulation.
4
Clinical Efficacy: High-Dose Tolerance and Deep Repair
Ordinary B1 requires extremely high doses ≥300 mg/day to treat diabetic neuropathy, but its efficacy is limited due to its absorption rate. Benfotiamine can stably increase tissue TPP concentration within the dose range of 150–600 mg/day. Clinical trials have shown that it can significantly improve nerve conduction velocity +2.1 m/s vs placebo and pain scores VAS reduced by 40%, and there is no report of liver and kidney toxicity (Diabetes Care, 2005).
5
Stability and Compatibility of Preparations
Benfotiamine is significantly more stable than ordinary B1 in an acidic environment (pH 2.0–4.0) — degradation rate <5% vs >30% — and is compatible with a variety of multivitamins or drug preparations. Its lipid-soluble properties support the development of delivery systems such as nanoemulsions and liposomes, further improving the efficiency of targeted delivery.
💬
Frequently Asked Questions
Q
What is benfotiamine and how does it differ from regular vitamin B1?
Benfotiamine is a synthetic, lipid-soluble derivative of vitamin B1 (thiamine). Unlike ordinary water-soluble thiamine, which relies on intestinal carriers for absorption and has a bioavailability of less than 5%, benfotiamine uses passive diffusion to cross intestinal membranes, achieving absorption rates above 80% and a bioavailability 3–5 times higher than regular B1.
Q
Why is benfotiamine more effective for nerve-related conditions than regular thiamine?
Benfotiamine's lipid-soluble structure allows it to penetrate the blood-brain barrier and nerve sheaths at 8–10 times the rate of ordinary B1. This makes it significantly more effective at acting on both the central and peripheral nervous systems, making it especially beneficial for conditions like diabetic peripheral neuropathy.
Q
How does benfotiamine help protect against diabetes-related complications?
Benfotiamine addresses diabetic complications through multiple mechanisms: it blocks the formation of advanced glycation end products (AGEs), suppresses inflammatory pathways (NF-κB, NLRP3 inflammasome), reduces oxidative stress by boosting glutathione reductase, and supports mitochondrial function by restoring pyruvate dehydrogenase complex (PDH) activity.
Q
What is the recommended dosage range for benfotiamine, and is it safe at higher doses?
Clinical studies have used benfotiamine in the dose range of 150–600 mg/day. Within this range, it effectively elevates tissue thiamine pyrophosphate (TPP) levels. Importantly, clinical trials have found no reports of liver or kidney toxicity, demonstrating a favorable safety profile compared to high-dose ordinary thiamine.
Q
Can benfotiamine be combined with other vitamins or medications?
Yes. Benfotiamine is compatible with a wide range of multivitamin formulations and pharmaceutical preparations. Its stability in acidic environments (pH 2.0–4.0) is far superior to ordinary B1 (degradation rate <5% vs >30%), making it well-suited for combination products. Its lipid-soluble nature also supports advanced delivery systems such as nanoemulsions and liposomes.
Q
What clinical evidence supports the use of benfotiamine for diabetic neuropathy?
Multiple peer-reviewed studies support benfotiamine's efficacy. A notable clinical trial published in Diabetes Care (2005) showed that benfotiamine supplementation significantly improved nerve conduction velocity by +2.1 m/s compared to placebo, and reduced pain scores (VAS) by 40%. Additional research published in Diabetes (2010) and Neurochem Res (2016) further validates its neuroprotective and anti-glycation effects.